Was Carmen Bozic’s Vertex (VRTX) share sale under a Rule 10b5-1 trading plan?

Yes. A footnote states that the transaction was made pursuant to Dr. Bozic’s company-approved trading plan under Rule 10b5-1. The plan was entered into on November 20, 2025, indicating the sale was pre-arranged rather than a spontaneous market decision.

Vertex Pharmaceuticals (VRTX) EVP and CMO sells 1,745 shares in planned trade

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold 1,745 shares of common stock in an open-market transaction at $450 per share. The sale on June 5, 2026 was made under a company-approved Rule 10b5-1 trading plan. After the sale, she directly holds 21,015 shares.

Insider Trade Summary 10b5-1

Net Seller: 1,745 shares ($785,250)

Net Sell 1 txn

Insider Bozic Carmen

Role EVP and CMO

Sold 1,745 shs ($785K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,745	$450.00	$785K

Holdings After Transaction: Common Stock — 21,015 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 1,745 shares Sale price: $450.00 per share Shares held after sale: 21,015 shares +1 more

4 metrics

Shares sold 1,745 shares Open-market sale on June 5, 2026

Sale price $450.00 per share Common stock transaction

Shares held after sale 21,015 shares Direct ownership post-transaction

Net shares sold 1,745 shares Net-sell direction in filing summary

Key Terms

Rule 10b5-1, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 regulatory

"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action: "open-market sale" for the common stock transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock" in the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/09/2026 - 04:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bozic Carmen

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/05/2026		S⁽¹⁾		1,745	D	$450	21,015	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vertex Pharmaceuticals (VRTX) report for Carmen Bozic?

Vertex Pharmaceuticals reported that EVP and CMO Carmen Bozic sold 1,745 shares of common stock. The open-market sale occurred at $450 per share, and was executed under a pre-established Rule 10b5-1 trading plan approved by the company.

How many Vertex (VRTX) shares did Carmen Bozic sell and at what price?

Carmen Bozic sold 1,745 shares of Vertex common stock at $450 per share. This was an open-market transaction, and the filing indicates it was carried out pursuant to a company-approved Rule 10b5-1 trading plan entered into on November 20, 2025.

How many Vertex (VRTX) shares does Carmen Bozic hold after this sale?

Following the reported sale, Carmen Bozic directly holds 21,015 shares of Vertex common stock. The Form 4 shows this post-transaction balance, providing context for the size of the sale relative to her remaining equity position in the company.

What role does Carmen Bozic hold at Vertex Pharmaceuticals (VRTX)?

Carmen Bozic serves as Executive Vice President and Chief Medical Officer at Vertex Pharmaceuticals. The Form 4 identifies her as an officer of the company, clarifying that this open-market sale reflects trading activity by a senior executive with direct share ownership.